DENTSPLY SIRONA Inc. — FY2020 Form 10-K Summary
Business context and reporting period
DENTSPLY SIRONA is a global dental products and technologies company operating in more than 120 countries through two reportable segments: Technologies & Equipment and Consumables. The filing covers the fiscal year ended December 31, 2020. Although the request identifies “2020 Q4,” this Form 10-K reports full-year results rather than standalone fourth-quarter results.
Approximately 90% of consolidated sales came from dental products and technologies, with the remainder primarily from healthcare consumables. Approximately two-thirds of sales were outside the United States. Henry Schein and Patterson represented approximately 24% of annual revenue combined.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Net sales | $3.342 billion | $4.029 billion | Down 17.1% |
| Gross profit | $1.657 billion | $2.165 billion | Down 23.5% |
| Gross margin | 49.6% | 53.7% | Down 410 basis points |
| Operating income | $(12) million | $361 million | Down $373 million |
| Net income attributable to DENTSPLY SIRONA | $(83) million | $263 million | Decline of $346 million |
| Diluted EPS | $(0.38) | $1.17 | Decline of $1.55 |
| Cash from operations | $635 million | $633 million | Up $2 million |
| Capital expenditures | $87 million | $123 million | Down $36 million |
Segment sales were $1.961 billion for Technologies & Equipment, down 14.1%, and $1.381 billion for Consumables, down 20.9%. Segment adjusted operating income declined 17.1% to $387 million and 28.6% to $314 million, respectively.
Cash and cash equivalents were $438 million at year-end, compared with $405 million in 2019. Total debt, including current and long-term portions, was $2.274 billion, compared with $1.433 billion, and net debt to total capitalization increased to 27.0% from 16.8%. The company had $1.173 billion of unused credit capacity and was in compliance with debt covenants at December 31, 2020.
Operating cash flow benefited from working-capital improvements, including lower receivable days of 54 versus 62 and lower inventory days of 102 versus 116. The company paid $88 million in dividends and repurchased $140 million of common stock, leaving $350 million remaining under its repurchase authorization.
Material changes versus the prior comparable period
- COVID-19 caused widespread dental-office closures, procedure reductions and lower customer demand. Sales reached their lowest level in April and improved during the second half of the year as practices reopened.
- Organic sales declined 16.7%, while reported sales benefited approximately 0.3% from currency and were reduced by approximately 0.6% from divestitures and 0.1% from discontinued products.
- Lower volume and unfavorable manufacturing variances reduced gross margin. Cost-containment actions partly offset the effect of lower sales.
- The company recorded a $157 million goodwill impairment charge and $39 million of indefinite-lived intangible-asset impairment charges, primarily related to the Equipment & Instruments reporting unit and COVID-19-driven changes in forecasts.
- The company acquired Byte, a direct-to-consumer clear-aligner business, on December 31, 2020 for approximately $1.0 billion, funded with cash. The preliminary purchase accounting included $631 million of goodwill and $416 million of intangible assets.
- The company issued $750 million of 3.25% senior unsecured notes due 2030 and used the proceeds primarily to repay its $700 million revolver draw.
- The restructuring program was expanded to exit traditional orthodontics and portions of the laboratory business. Total expected program charges increased to approximately $375 million, with anticipated annual cost savings of approximately $250 million.
Guidance, outlook, commentary and risks
Management’s restructuring objectives include annualized net sales growth of 3% to 4%, adjusted operating income margins of 22% by the end of 2022, and annual cost savings of approximately $250 million. The company expects 2021 capital expenditures of approximately $135 million to $160 million and restructuring-related cash payments of approximately $50 million to $100 million. No specific full-year 2021 revenue or earnings guidance is provided in the filing.
Management expects sufficient liquidity for the next twelve months, but warns that a prolonged pandemic recovery could impair covenant compliance and require covenant waivers. COVID-19 remains the principal near-term uncertainty, including possible restrictions, reduced dental utilization, supply-chain disruption, customer credit deterioration and pressure on liquidity.
Other significant risks include distributor concentration, foreign-exchange exposure, substantial indebtedness, debt covenant and refinancing risk, goodwill and intangible-asset impairment, regulatory approval and Medical Device Regulation compliance, cybersecurity, product liability, competition, tariffs, restructuring execution and integration of Byte.
Material contingencies include an unresolved IRS dispute involving a $546 million worthless-stock deduction and potential additional tax exposure, and a Swedish tax dispute involving approximately $57 million of potential tax expense. The company also faces securities litigation and other product, intellectual-property, employment and commercial claims, although management does not currently believe these matters will materially affect consolidated results.
The company discontinued sales of all dental amalgam products by December 2020 following evolving health and regulatory concerns. In January 2021, it acquired Datum Dental for $95 million, with potential additional earn-out payments of up to $10 million.
Investor verification checklist
- Verify the pace and durability of post-pandemic dental procedure recovery and the effect of renewed restrictions.
- Assess whether restructuring actions achieve the targeted $250 million of annual savings without impairing revenue, innovation or customer relationships.
- Review Byte’s integration, customer-acquisition economics, clear-aligner growth and any final purchase-price allocation changes.
- Monitor goodwill and intangible-asset sensitivity, especially the Implants and Equipment & Instruments reporting units.
- Reconcile debt maturities, interest costs, covenant ratios and available revolving-credit capacity.
- Track the IRS and Swedish tax disputes, securities litigation and other contingencies for potential cash or earnings impacts.
- Evaluate dependence on Henry Schein, Patterson and other distributors, including distributor inventory levels and private-label competition.
- Confirm that reported sales and earnings comparisons distinguish GAAP results from non-GAAP organic sales and adjusted operating income.